JP2002508183A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508183A5
JP2002508183A5 JP2000539141A JP2000539141A JP2002508183A5 JP 2002508183 A5 JP2002508183 A5 JP 2002508183A5 JP 2000539141 A JP2000539141 A JP 2000539141A JP 2000539141 A JP2000539141 A JP 2000539141A JP 2002508183 A5 JP2002508183 A5 JP 2002508183A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
nucleic acid
amino acids
ulbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000539141A
Other languages
English (en)
Japanese (ja)
Other versions
JP4255211B2 (ja
JP2002508183A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/027048 external-priority patent/WO1999031241A1/en
Publication of JP2002508183A publication Critical patent/JP2002508183A/ja
Publication of JP2002508183A5 publication Critical patent/JP2002508183A5/ja
Application granted granted Critical
Publication of JP4255211B2 publication Critical patent/JP4255211B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000539141A 1997-12-17 1998-12-17 ヒトb細胞リンパ腫に関連した細胞表面糖タンパク質−ulbp、dna及びポリペプチド Expired - Fee Related JP4255211B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6985797P 1997-12-17 1997-12-17
US9294698P 1998-07-15 1998-07-15
US60/069,857 1998-07-15
US60/092,946 1998-07-15
PCT/US1998/027048 WO1999031241A1 (en) 1997-12-17 1998-12-17 Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides

Publications (3)

Publication Number Publication Date
JP2002508183A JP2002508183A (ja) 2002-03-19
JP2002508183A5 true JP2002508183A5 (enExample) 2006-02-02
JP4255211B2 JP4255211B2 (ja) 2009-04-15

Family

ID=26750491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539141A Expired - Fee Related JP4255211B2 (ja) 1997-12-17 1998-12-17 ヒトb細胞リンパ腫に関連した細胞表面糖タンパク質−ulbp、dna及びポリペプチド

Country Status (12)

Country Link
US (7) US6653447B1 (enExample)
EP (1) EP1037991B1 (enExample)
JP (1) JP4255211B2 (enExample)
AT (1) ATE305510T1 (enExample)
AU (1) AU742757C (enExample)
CA (1) CA2315251A1 (enExample)
DE (1) DE69831754T2 (enExample)
DK (1) DK1037991T3 (enExample)
ES (1) ES2251120T3 (enExample)
IL (2) IL136621A0 (enExample)
NZ (1) NZ505500A (enExample)
WO (1) WO1999031241A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1368978A (zh) * 1999-03-15 2002-09-11 武田药品工业株式会社 新蛋白质及其应用
WO2002062997A1 (fr) * 2001-02-05 2002-08-15 Takeda Chemical Industries, Ltd. Nouvelle proteine et son utilisation
US6821522B2 (en) * 2001-05-31 2004-11-23 The Regents Of The University Of California Tumor Therapy
US7364890B2 (en) 2001-07-28 2008-04-29 Midwest Research Institute Thermal tolerant avicelase from Acidothermus cellulolyticus
WO2003029436A2 (en) 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4
EP1578923A4 (en) * 2002-04-22 2009-01-21 Hutchinson Fred Cancer Res SOLUBLE MIC POLYPEPTIDE AS A MARKER FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR DISEASES
US20060247420A1 (en) * 2002-09-04 2006-11-02 George Coukos Immune cell recptor ligand and immune cell receptor
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1413316A1 (en) * 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
KR101199789B1 (ko) * 2003-03-24 2012-11-09 더 스크립스 리서치 인스티튜트 종양 성장 억제 dna 백신
US7666417B2 (en) * 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
GB0403491D0 (en) * 2004-02-17 2004-03-24 Univ Cambridge Tech Polypeptides, methods and means
US7998481B2 (en) * 2004-04-05 2011-08-16 The Regents Of The University Of California Modulation of NKG2D for treating or preventing solid organ allograft rejection
CA2563313C (en) * 2004-04-05 2014-06-03 The Regents Of The University Of California Modulation of nkg2d
WO2006056480A2 (en) 2004-11-29 2006-06-01 Klinikum Der Universität Regensburg Means and methods for detecting methylated dna
CN101124338B (zh) 2004-11-29 2011-05-04 雷根斯堡大学临床中心 用于检测甲基化dna的试剂盒和方法
US20070071759A1 (en) * 2005-06-29 2007-03-29 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
WO2007143245A2 (en) 2006-06-01 2007-12-13 Midwest Research Institute An l-arabinose fermenting yeast
WO2008103392A2 (en) 2007-02-21 2008-08-28 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
US20110038865A1 (en) * 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
US9611313B2 (en) 2007-06-26 2017-04-04 University Of Miami Antibody-endostatin fusion protein and its variants
US8070021B2 (en) * 2007-10-31 2011-12-06 Momentive Performance Materials Hydraulic container evacuator and method
KR20110137290A (ko) 2009-01-08 2011-12-22 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
US20130101590A1 (en) 2010-04-09 2013-04-25 Heather A. Arnett Btnl9 proteins, nucleic acids, and antibodies and uses thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2013036799A2 (en) * 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
MX366178B (es) 2012-07-19 2019-07-01 Amgen Inc Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
AU2014296288B2 (en) 2013-07-31 2020-02-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
ES2810800T3 (es) 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
US11117969B2 (en) * 2014-12-05 2021-09-14 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
CA3204990A1 (en) 2014-12-05 2016-06-09 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
WO2017075329A2 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
AR107469A1 (es) 2016-01-27 2018-05-02 Oncorus Inc Vectores virales oncolíticos y sus usos
EP3468588A4 (en) 2016-06-14 2019-12-11 University of Pittsburgh - of The Commonwealth System of Higher Education EXPRESSION OF NKG2D-ACTIVATING LIGAND PROTEINS FOR THE SENSITIZATION OF CANCER CELLS FOR THE ATTACK THROUGH CYTOTOXIC IMMUNOCELLS
BR112019000015A2 (pt) 2016-06-30 2019-04-24 Oncorus, Inc. distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
US10829789B2 (en) 2016-12-21 2020-11-10 Creatus Biosciences Inc. Methods and organism with increased xylose uptake
AU2017383557A1 (en) 2016-12-21 2019-08-08 Creatus Biosciences Inc. Xylitol producing Metschnikowia species
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
EP3658165A4 (en) 2017-07-26 2021-09-01 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND THEIR USES
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
JOP20200234A1 (ar) 2018-03-27 2020-09-15 Xyphos Biosciences Inc نطاقات a1-a2 معدلة لمركبات ترابطية nkg2d غير طبيعية ترتبط بمستقبلات nkg2d غير طبيعية.
WO2020051013A2 (en) * 2018-08-24 2020-03-12 The Trustees Of Columbia University In The City Of New York Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
EP4479080A1 (en) 2022-02-16 2024-12-25 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
USRE38824E1 (en) * 1986-08-04 2005-10-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies against human herpes virus-6(HHV-6) and method of use
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5464771A (en) * 1994-04-29 1995-11-07 The United States Of America As Represented By The Secretary Of Agriculture Biologically pure culture of Actinomyces viscosus strain used for the bioremediation of chlorinated hydrocarbons
WO1997038110A2 (en) * 1996-04-05 1997-10-16 Kieta Holding S.A. Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases
US5912415A (en) * 1996-05-16 1999-06-15 Regents Of The University Of Minnesota Arabidopsis spindly gene, methods of identification and use
US6930170B2 (en) * 1997-06-16 2005-08-16 Genentech, Inc. PRO1184 polypeptides

Similar Documents

Publication Publication Date Title
JP2002508183A5 (enExample)
Bringman et al. Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes
KR101700970B1 (ko) 지혈 활성을 가지고 혈소판 응집을 유도할 수 있는 재조합 단백질
Benech et al. 3'end structure of the human (2'-5') oligo A synthetase gene: prediction of two distinct proteins with cell type-specific expression
CA2190371A1 (en) Receptor for oncostatin m
CA2318482A1 (en) Il-18 receptors
JP2002500886A5 (enExample)
JP2002502589A5 (enExample)
JP2001511347A5 (enExample)
JP2005046146A5 (enExample)
JP2002508970A5 (enExample)
CA2309783A1 (en) Fibroblast growth factor-19
JP2002514418A5 (enExample)
JP2002536018A5 (enExample)
WO2000023565B1 (en) Novel neuropilin/growth factor binding and uses thereof
JP2005523681A5 (enExample)
Ehlert et al. Novel C-terminally truncated isoforms of the CXC chemokine β-thromboglobulin and their impact on neutrophil functions
JP2004532037A5 (enExample)
CA2439452A1 (en) High-affinity antagonists of elr-cxc chemokines
KR920012440A (ko) 인간 인터류킨-5 수용체
JP2003531634A5 (enExample)
Ehlert et al. Limited and Defined Truncation at the C Terminus Enhances Receptor Binding and Degranulation Activity of the Neutrophil-activating Peptide 2 (NAP-2): COMPARISON OF NATIVE AND RECOMBINANT NAP-2 VARIANTS (∗)
RU2001117860A (ru) ГЕНЫ ГОМОЛОГИЧНЫХ ИММУНОДОМИНАНТНЫХ БЕЛКОВ МАССОЙ 28-КИЛОДАЛЬТОН Ehrlichia canis И ИХ ПРИМЕНЕНИЕ
Gull et al. Heterologous expression, immunochemical and computational analysis of recombinant human interferon alpha 2b
CN102775502A (zh) α干扰素融合蛋白